Neurobiological Technologies Stock Performance
| NTII Stock | USD 0.0001 0.00 0.00% |
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Neurobiological Technologies are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Neurobiological Technologies has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong forward indicators, Neurobiological Technologies is not utilizing all of its potentials. The newest stock price confusion, may contribute to short-horizon losses for the traders. ...more
Last Split Factor 1:7 | Dividend Date 2012-12-27 | Last Split Date 2007-09-17 |
1 | Acquisition by Highland Capital Management Lp of 20500 shares of Neurobiological Technologies at 2.58 subject to Rule 16b-3 | 12/29/2025 |
Neurobiological | Build AI portfolio with Neurobiological Stock |
Neurobiological Technologies Relative Risk vs. Return Landscape
If you would invest 0.01 in Neurobiological Technologies on October 31, 2025 and sell it today you would earn a total of 0.00 from holding Neurobiological Technologies or generate 0.0% return on investment over 90 days. Neurobiological Technologies is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Neurobiological, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neurobiological Technologies Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Neurobiological Technologies for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Neurobiological Technologies can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Neurobiological Technologies generated a negative expected return over the last 90 days | |
| Neurobiological Technologies has some characteristics of a very speculative penny stock | |
| Neurobiological Technologies is unlikely to experience financial distress in the next 2 years |
Neurobiological Technologies Fundamentals Growth
Neurobiological Stock prices reflect investors' perceptions of the future prospects and financial health of Neurobiological Technologies, and Neurobiological Technologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neurobiological Stock performance.
| Return On Equity | 1.0 | ||||
| Profit Margin | 0.74 % | ||||
| Operating Margin | 0.77 % | ||||
| Current Valuation | 5.43 M | ||||
| Shares Outstanding | 27.02 M | ||||
| Price To Book | 0.07 X | ||||
| Price To Sales | 0.0001 X | ||||
| Revenue | 6.03 M | ||||
| Gross Profit | 25.32 M | ||||
| EBITDA | 19.54 M | ||||
| Net Income | 4.94 M | ||||
| Cash And Equivalents | 26.49 M | ||||
| Cash Per Share | 0.98 X | ||||
| Total Debt | 1.04 M | ||||
| Book Value Per Share | 1.07 X | ||||
| Cash Flow From Operations | 4.78 M | ||||
| Market Capitalization | 2.7 K | ||||
| Total Asset | 2.58 M | ||||
| Working Capital | (73 K) | ||||
| Current Liabilities | 73 K | ||||
About Neurobiological Technologies Performance
By evaluating Neurobiological Technologies' fundamental ratios, stakeholders can gain valuable insights into Neurobiological Technologies' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Neurobiological Technologies has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Neurobiological Technologies has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.11 | 0.12 | |
| Return On Capital Employed | 0.13 | 0.14 | |
| Return On Assets | 0.11 | 0.12 | |
| Return On Equity | 0.12 | 0.13 |
Things to note about Neurobiological Technologies performance evaluation
Checking the ongoing alerts about Neurobiological Technologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neurobiological Technologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neurobiological Technologies generated a negative expected return over the last 90 days | |
| Neurobiological Technologies has some characteristics of a very speculative penny stock | |
| Neurobiological Technologies is unlikely to experience financial distress in the next 2 years |
- Analyzing Neurobiological Technologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neurobiological Technologies' stock is overvalued or undervalued compared to its peers.
- Examining Neurobiological Technologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neurobiological Technologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neurobiological Technologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neurobiological Technologies' stock. These opinions can provide insight into Neurobiological Technologies' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Neurobiological Stock analysis
When running Neurobiological Technologies' price analysis, check to measure Neurobiological Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurobiological Technologies is operating at the current time. Most of Neurobiological Technologies' value examination focuses on studying past and present price action to predict the probability of Neurobiological Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurobiological Technologies' price. Additionally, you may evaluate how the addition of Neurobiological Technologies to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |